{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from United States, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:f1b6f4c66791654a3858dd5b3bd23b8bd97f1d61afccb34a9e270aeaa87e0601", "url": "https://seekingalpha.com/news/4633431-im-cannabis-reports-q2-results?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633431-im-cannabis-reports-q2-results?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "IM Cannabis reports Q2 results", "content_text": "IM Cannabis press release [https://seekingalpha.com/filing/309949813] (IMCC [https://seekingalpha.com/symbol/IMCC]): Q2 revenue of $7.6 million, compared to $12.7 million in the same period in 2025. * Gross profit of $1.5 million, compared to $3.4 million in the same period in 2025. * Operating loss of $2.1 million, compared to $0.4 million in the same period in 2025. * Net loss of $4.4 million, or $0.47 per share (basic and diluted), compared to a net loss of $0.2 million, or $0.09 per share, in the same period in 2025. MORE ON IM CANNABIS * IM Cannabis raises $225,000 through convertible not", "date_published": "2026-08-14T16:48:01+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "IMCC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMCC", "name": "Im Cannabis Corp", "sentiment_url": "https://sharemaestro.com/sentiment/833d58bb-24b2-49c2-bc1b-67a13a4e0456/"}]}}, {"id": "source:2792d6ef5c2e50e7e11472a10c57c26410263e5225b8879409701e89fad83d6e", "url": "https://finance.yahoo.com/healthcare/articles/reasons-hold-hinge-health-stock-153600785.html", "external_url": "https://finance.yahoo.com/healthcare/articles/reasons-hold-hinge-health-stock-153600785.html", "title": "Reasons to Hold Hinge Health Stock in Your Portfolio for Now", "content_text": "Hinge Health HNGE is well-positioned for sustained growth, driven by robust revenue growth, expanding opportunities in Migraine and gastrointestinal (GI) care and a scalable AI-powered MSK platform. The raised 2026 outlook, broader enterprise reach and growing sales pipeline further support the growth outlook. However, continued investments and Cylinder Health integration could weigh on margin expansion. This Zacks Rank #3 (Hold) company's shares have surged 88.2% in the year-to-date period compared with the 2.4% growth of the industry. The S&P 500 Composite has increased 12.8% during the said", "date_published": "2026-08-14T15:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PAHC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PAHC", "name": "Phibro Animal Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/064612ef-ec89-469d-8e5b-b34c033cf092/"}]}}, {"id": "source:7a92c6b19227f993f9d52ad3ce521cc34e10bddf97df9b2d301ee4f7b1588245", "url": "https://finance.yahoo.com/healthcare/articles/solv-plans-health-information-systems-153500752.html", "external_url": "https://finance.yahoo.com/healthcare/articles/solv-plans-health-information-systems-153500752.html", "title": "SOLV Plans Health Information Systems Business Spinoff to Drive Growth", "content_text": "Solventum SOLV plans to separate its Health Information Systems (HIS) business as part of its portfolio optimization strategy. The move is expected to sharpen the company's focus on its core MedSurg and Dental Solutions businesses while allowing HIS to pursue its growth opportunities as a standalone entity. From an investor perspective, the planned separation could unlock shareholder value by creating a more focused MedTech business and enabling targeted capital allocation toward Solventum's higher-priority growth areas. HIS, which generates $1.4 billion in annual sales and serves more than 75", "date_published": "2026-08-14T15:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PAHC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PAHC", "name": "Phibro Animal Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/064612ef-ec89-469d-8e5b-b34c033cf092/"}]}}, {"id": "source:2bbfb8e944a917d519505f6e563f6028bb7ec27ee39686f959bc726292ae6904", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-hims-raised-guidance-151415471.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-hims-raised-guidance-151415471.html", "title": "Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset?", "content_text": "Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 6% in extended trading on August 10 after the telehealth company delivered another quarter of rapid growth alongside sharply weaker profitability. Revenue rose 38% year over year to $753.2 million, subscribers increased 19% to 2.89 million, and Monthly Revenue per Average Subscriber climbed 21% to $92. The company also raised its full-year revenue outlook to $3.1 billion to $3.3 billion from $2.8 billion to $3.0 billion. The earnings line told a different story. Hims reported an $86.3 million net loss, equal to 37 cents per share, compared ", "date_published": "2026-08-14T15:14:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "HIMS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "Hims Hers Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/494d8676-2cc6-4860-bdb4-37e9e4702e1f/"}]}}, {"id": "source:56e5764ee72839841bf4e92be4cf7650854aab0fcbff217d52e37ac14404a810", "url": "https://finance.yahoo.com/healthcare/articles/amylyx-pharmaceuticals-amlx-down-7-051026270.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amylyx-pharmaceuticals-amlx-down-7-051026270.html", "title": "Amylyx Pharmaceuticals (AMLX) Is Down 7.1% After Wider Q2 Loss And Avexitide Phase III Update", "content_text": "Amylyx Pharmaceuticals reported a wider Q2 2026 net loss of US$43.42 million, though the loss per share improved. The company is advancing towards a pivotal Phase III data readout for avexitide in post-bariatric hypoglycemia, with potential commercialization targeted for 2027 if approved. This upcoming data readout is a key catalyst, with success potentially leading to accelerated regulatory filing and revenue, while failure would prolong the company's pre-revenue status.", "date_published": "2026-08-14T15:11:52+00:00", "authors": [{"name": "Market source"}], "tags": ["Earnings", "AMLX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMLX", "name": "Amylyx Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/9542732c-dd8b-415f-9b0f-63df1f29d967/"}]}}, {"id": "source:454e441e5c05a4eed962c9b68d89915dae9e02ce2fa00c915f7ae52f7adf8cab", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBYTmxoSnhPdkFXNHRSXzVkX1E4aUFXcnZIMHZ3NWswOVZadjFFMDZJRGRTMXppNm8tTmw0NFRWLWNqTElJT2dmV0N3Q0Y0T29xRDN2bEkxOXdnNzNZaFk4M3gzOUpaZTlNX3pQYVZlTWkySUxPamptV3I4QkZ4YUU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBYTmxoSnhPdkFXNHRSXzVkX1E4aUFXcnZIMHZ3NWswOVZadjFFMDZJRGRTMXppNm8tTmw0NFRWLWNqTElJT2dmV0N3Q0Y0T29xRDN2bEkxOXdnNzNZaFk4M3gzOUpaZTlNX3pQYVZlTWkySUxPamptV3I4QkZ4YUU?oc=5", "title": "Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop", "content_text": "Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop", "date_published": "2026-08-14T13:47:41+00:00", "authors": [{"name": "Pluang"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "Hims Hers Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/494d8676-2cc6-4860-bdb4-37e9e4702e1f/"}]}}, {"id": "source:716db2c758fe7563d890b3fd84cd08700f39c2dc0800cb2ca92c80723134e873", "url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Lantheus gains FDA nod for tau PET imaging agent in Alzheimer\u2019s", "content_text": "[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer\u2019s disease through positron emission tomography (PET). Specifically, the approval allows the use of Tauklarify in cognitively impaired adults who are investigated for Alzheimer\u2019s disease to detect if there is any tau neurofibrillary tangle pathology causing the condition. Patients should undergo diagnostic tests, such as PET scans, to determine t", "date_published": "2026-08-14T12:31:50+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "LNTH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LNTH", "name": "Lantheus Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/41a59536-c8b5-4d85-a0e6-acfdd4b6ccea/"}]}}, {"id": "source:c2732936f28167b570efd9641ca2304365fff2c1225226bd6743c845f7f36a42", "url": "https://seekingalpha.com/news/4633062-eton-pharmaceuticals-jumps-on-strong-q2-print-2026-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633062-eton-pharmaceuticals-jumps-on-strong-q2-print-2026-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Eton Pharmaceuticals jumps on strong Q2 print, 2026 guidance", "content_text": "Shares in Eton Pharmaceuticals (ETON [https://seekingalpha.com/symbol/ETON]) rallied 25% in premarket trading on Friday, driven by a solid quarterly print and 2026 revenue forecast, which the company said would exceed $145M while targeting adjusted EBITDA margin above 35%. Chief executive officer Sean Brynjelsen said the company delivered \u201crecord revenue, significant margin expansion, and important progress across both our commercial portfolio and pipeline,\u201d while also completing \u201cseveral strategic transactions\u201d intended to support long-term growth. On longer-term profitability, Brynjelsen sai", "date_published": "2026-08-14T09:13:08+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:18bebb725b31d7280db91100fc99878e394ed9eeb596734f0884478760a987cd", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold", "content_text": "ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold", "date_published": "2026-08-14T08:44:29+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Earnings", "ANIP"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ANIP", "name": "ANI Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/fb694c05-9d9d-4bb4-a412-86d9b0bc952d/"}]}}, {"id": "source:7d651f96889931ce41c3760ea642c690f4498e1e59c39efee8411b63b8227b63", "url": "https://stockstory.org/us/stocks/nasdaq/anip/news/earnings-call/the-top-5-analyst-questions-from-ani-pharmaceuticalss-q2-earnings-call", "external_url": "https://stockstory.org/us/stocks/nasdaq/anip/news/earnings-call/the-top-5-analyst-questions-from-ani-pharmaceuticalss-q2-earnings-call", "title": "The Top 5 Analyst Questions From ANI Pharmaceuticals\u2019s Q2 Earnings Call", "content_text": "ANI Pharmaceuticals reported strong Q2 year-on-year growth in its rare disease and generics businesses, exceeding analyst estimates for revenue, EPS, and EBITDA, though the market reacted negatively. CEO Nikhil Lalwani highlighted significant momentum in demand for Cortrophin Gel. Analysts focused on the gout expansion, prescription data disconnects, revised Cortrophin guidance, conversion of new cases to prescriptions, and the impact of insurance reverification issues.", "date_published": "2026-08-14T07:41:25+00:00", "authors": [{"name": "StockStory"}], "tags": ["Earnings", "ANIP"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ANIP", "name": "ANI Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/fb694c05-9d9d-4bb4-a412-86d9b0bc952d/"}]}}, {"id": "source:0e500e07b836c36847b9921bbc7d3b1ed91baf40ff85d6757bcb57dd591769e3", "url": "https://seekingalpha.com/news/4633035-eton-pharmaceuticals-forecasts-2026-revenue-to-exceed-145m-while-targeting-adjusted-ebitda?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633035-eton-pharmaceuticals-forecasts-2026-revenue-to-exceed-145m-while-targeting-adjusted-ebitda?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35%", "content_text": "Earnings Call Insights: Eton Pharmaceuticals (ETON) Q2 2026 MANAGEMENT VIEW * CEO Sean Brynjelsen said the company delivered \u201crecord revenue, significant margin expansion and important progress across both our commercial portfolio and pipeline,\u201d while also completing \u201cseveral strategic transactions\u201d intended to support long-term growth. * Brynjelsen highlighted Q2 revenue of $37.6 million and said management is \u201conce again raising our 2026 revenue guidance\u201d to \u201cfull year revenue to exceed $145 million,\u201d up from \u201cmore than $120 million,\u201d alongside an adjusted EBITDA margin outlook now expected ", "date_published": "2026-08-14T05:47:54+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:eb9741a0d5cfe4938b9147119f6b237f56e5a504b868d4bb2108554ba2f75e0f", "url": "https://finance.yahoo.com/markets/stocks/articles/5-must-read-analyst-questions-051700343.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/5-must-read-analyst-questions-051700343.html", "title": "5 Must-Read Analyst Questions From Elanco\u2019s Q2 Earnings Call", "content_text": "5 Must-Read Analyst Questions From Elanco's Q2 Earnings Call Elanco's results for the second quarter were positively received by the market, reflecting momentum across both its Pet Health and Farm Animal businesses. Management attributed growth to strong execution in the U.S. and international markets, particularly the success of new products like Zenrelia and Credelio Quattro. CEO Jeffrey Simmons noted that \"Zenrelia was the largest contributor to second quarter total Elanco growth,\" with broad-based gains from innovative treatments and share gains in core categories such as dermatology and p", "date_published": "2026-08-14T05:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ELAN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ELAN", "name": "Elanco Animal Health", "sentiment_url": "https://sharemaestro.com/sentiment/00195b94-56e2-484e-b914-5183cf626108/"}]}}, {"id": "source:7166eb73ce8f8aaf457a4c7383633c489c0e2b8222045c0673df26252962b9f3", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPMTdlYnNrVWJSQ1RxR2c1N29LdndndkVGZmdqOHZVR0UtY3JLQTRoSDdNSUU2WlpqS2hVUXVGOEdHTjVQSS0xcTdaQTZ5ZEE1eDlYaDRvNFVLV3BXUl8xUmxHNlRzdkJkZUxPT1JGRTlwMWM4ejE2OEJmMG8tVUZDLURQcV9GR1lJaTA3VzFB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPMTdlYnNrVWJSQ1RxR2c1N29LdndndkVGZmdqOHZVR0UtY3JLQTRoSDdNSUU2WlpqS2hVUXVGOEdHTjVQSS0xcTdaQTZ5ZEE1eDlYaDRvNFVLV3BXUl8xUmxHNlRzdkJkZUxPT1JGRTlwMWM4ejE2OEJmMG8tVUZDLURQcV9GR1lJaTA3VzFB?oc=5", "title": "Eton Pharmaceuticals Q2 2026 Earnings Call Transcript", "content_text": "Eton Pharmaceuticals Q2 2026 Earnings Call Transcript", "date_published": "2026-08-14T03:22:42+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:c6c39d169145e04ad91353134aa787d04fba9e66b7755767462f2e63151d4c03", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQaDVObV8tYVZybUk1cTdRNHdxRWFucGpFYUtrSDJBUTJDWHhTNEVlT0JnNDBTQm4xcTM2Y3dwb0hsdDZTUVlRcGE3UVlnQVA1cUNsdGdBaEpwOXNMMnFEX0dYX2FWTUFWSG1ZVGhpMDREMWRJOXhPQ0VFWlRSRlZwSnVhYnJKWXIzYjk0bDNmdmdrN2I2cWtsTnFKMF84WHdLU1ExWjhYZzg1SzVVdUsxWmtKUkRKMEEzQ2tqS080R0xGaVBO?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQaDVObV8tYVZybUk1cTdRNHdxRWFucGpFYUtrSDJBUTJDWHhTNEVlT0JnNDBTQm4xcTM2Y3dwb0hsdDZTUVlRcGE3UVlnQVA1cUNsdGdBaEpwOXNMMnFEX0dYX2FWTUFWSG1ZVGhpMDREMWRJOXhPQ0VFWlRSRlZwSnVhYnJKWXIzYjk0bDNmdmdrN2I2cWtsTnFKMF84WHdLU1ExWjhYZzg1SzVVdUsxWmtKUkRKMEEzQ2tqS080R0xGaVBO?oc=5", "title": "United Therapeutics CEO Rothblatt sells $4.89m in stock", "content_text": "United Therapeutics CEO Rothblatt sells $4.89m in stock", "date_published": "2026-08-14T03:15:00+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Market update", "UTHR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UTHR", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/fbffdb96-6605-4c75-a92b-ecbfdce86d82/"}]}}, {"id": "source:59d193610c7dfd3ed709d44a86bfcb2af04a52ab7a8a107f65c85d18932c7a9e", "url": "https://www.gurufocus.com/news/9033570/ani-pharmaceuticals-anip-insider-sell-sr-vp-general-counsel-sec-meredith-cook-sells-500-shares", "external_url": "https://www.gurufocus.com/news/9033570/ani-pharmaceuticals-anip-insider-sell-sr-vp-general-counsel-sec-meredith-cook-sells-500-shares", "title": "ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares", "content_text": "Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals (ANIP), sold 500 shares of the company stock for approximately $37,740. This transaction is part of a broader trend of insider selling at ANI Pharmaceuticals, with 48 insider sells and zero buys over the past year. Despite this, GuruFocus valuation model indicates the stock is modestly undervalued, trading at $75.48 against a GF Value of $96.55.", "date_published": "2026-08-14T02:41:26+00:00", "authors": [{"name": "GuruFocus"}], "tags": ["Earnings", "ANIP"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ANIP", "name": "ANI Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/fb694c05-9d9d-4bb4-a412-86d9b0bc952d/"}]}}, {"id": "source:1d18efd759d5f83098577c037b2e6fd00c1fc27874e067816365a78f892e77c5", "url": "https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-c9cb8344e83b.html", "external_url": "https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-c9cb8344e83b.html", "title": "ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan", "content_text": "Meredith Cook, Senior Vice President, General Counsel and Secretary at ANI Pharmaceuticals (ANIP), sold 500 shares of common stock at $75.48 per share on August 13, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Cook directly holds 74,424 shares of ANI Pharmaceuticals common stock.", "date_published": "2026-08-14T02:10:12+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "ANIP"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ANIP", "name": "ANI Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/fb694c05-9d9d-4bb4-a412-86d9b0bc952d/"}]}}, {"id": "source:e07bb8bfab0a3a1d73f7ae037ceeceb1b2f7ebeeca6b33639547763a744fa284", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders", "content_text": "What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders", "date_published": "2026-08-14T01:43:52+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Guidance", "AMRX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMRX", "name": "Amneal Pharmaceuticals, Inc. Class A Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/eb64bade-4c9e-49a5-a30d-539ebca2200e/"}]}}, {"id": "source:38b2b65563849aa2a4c98dd03198981bfd00623d162eaf406b3e5fa63d8e6547", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-e952d74e5a67.html", "external_url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-e952d74e5a67.html", "title": "Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings", "content_text": "Amneal Pharmaceuticals director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on August 11, 2026. The shares were sold at a weighted average price of $17.18, with individual trades ranging from $17.07 to $17.31. Following this transaction, Buchi indirectly holds 93,499 shares through a trust and directly holds 75,077 shares.", "date_published": "2026-08-14T01:35:40+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "AMRX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMRX", "name": "Amneal Pharmaceuticals, Inc. Class A Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/eb64bade-4c9e-49a5-a30d-539ebca2200e/"}]}}, {"id": "source:100543e2802ab1309380779a54d9c50b2233245f8f76ab18cc001c416978b5fa", "url": "https://natlawreview.com/press-releases/kaplan-fox-investigating-hims-hers-health-inc-nyse-hims-potential-0", "external_url": "https://natlawreview.com/press-releases/kaplan-fox-investigating-hims-hers-health-inc-nyse-hims-potential-0", "title": "Kaplan Fox is Investigating Hims & Hers Health, Inc. (NYSE: HIMS) for Potential Securities Law Violations", "content_text": "Kaplan Fox & Kilsheimer LLP is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. This investigation follows a lawsuit filed by the FTC and California/Utah authorities alleging that Hims & Hers failed to clearly disclose prescription charges, made it difficult to cancel subscriptions, and misled consumers about health data privacy by sharing information with third parties. Following this news, Hims & Hers stock dropped by 14.73%.", "date_published": "2026-08-14T01:11:58+00:00", "authors": [{"name": "The National Law Review"}], "tags": ["Regulatory and legal", "HIMS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "Hims Hers Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/494d8676-2cc6-4860-bdb4-37e9e4702e1f/"}]}}, {"id": "source:633745e384ceeba03a915dd6adfc9e10fafdaabe01d7ff3b4a9c9affcd254d5d", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPYUt6UkltekM5Q3JMT0w1S0gzbWlGbzZQcy00MXlwY0VvMVY4M2ZSZGo4OVFvUHlUVm9HS0oxWWdSSzktcjRYZi1SWl9ZSXhEckFsNG9HUmg1bjBIcHVpVUEzYTBwRWhZV29BUnBvM0FOQlNnZEtrNDdaUFpxMlhBazJoSEM5U1JyS21Qb2xyYUstMUtUanRsX0doNWhjOExXMHZQMVp4V2dKVnNP?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPYUt6UkltekM5Q3JMT0w1S0gzbWlGbzZQcy00MXlwY0VvMVY4M2ZSZGo4OVFvUHlUVm9HS0oxWWdSSzktcjRYZi1SWl9ZSXhEckFsNG9HUmg1bjBIcHVpVUEzYTBwRWhZV29BUnBvM0FOQlNnZEtrNDdaUFpxMlhBazJoSEM5U1JyS21Qb2xyYUstMUtUanRsX0doNWhjOExXMHZQMVp4V2dKVnNP?oc=5", "title": "ETON PHARMACEUTICALS ($ETON) Releases Q2 2026 Earnings, Stock Rises", "content_text": "ETON PHARMACEUTICALS ($ETON) Releases Q2 2026 Earnings, Stock Rises", "date_published": "2026-08-13T22:51:00+00:00", "authors": [{"name": "Quiver Quantitative"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:586e4e5716216c462a6764f2c61c62a610234aa41cc875b4b6217574951ca7d1", "url": "https://kalkinemedia.com/us/news/announcements/ani-pharmaceuticals-senior-vp-meredith-cook-sells-500-shares-via-10b5-1-trading-plan", "external_url": "https://kalkinemedia.com/us/news/announcements/ani-pharmaceuticals-senior-vp-meredith-cook-sells-500-shares-via-10b5-1-trading-plan", "title": "ANI Pharmaceuticals Senior VP Meredith Cook Sells 500 Shares via 10b5-1 Trading Plan", "content_text": "Meredith Cook, Senior Vice President, General Counsel, and Secretary of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 500 shares of the company's common stock on August 13, 2026. The sale, executed under a pre-established Rule 10b5-1 trading plan adopted on September 15, 2025, occurred at a price of $75.48 per share. Following this transaction, Cook directly retains 74,424 shares of ANI Pharmaceuticals common stock.", "date_published": "2026-08-13T22:10:12+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Market update", "ANIP"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ANIP", "name": "ANI Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/fb694c05-9d9d-4bb4-a412-86d9b0bc952d/"}]}}, {"id": "source:7027c32006f6ebcf95bf6515dcf8892f6d76d9b46dc1ed75f7d2f6b26140c585", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOaDY1Y3F1Tnl0V2FiWGswQUIxLVNLdzlyNHNtMnNqLTF6cUxiSUxCYlZHTEIyaWhrN002TVFNN2dERk1Wc3BPa2FUNEItLWljVU1UM0ZvWlctVFlHaTJkNHIyMWRWd2paX1RIa0tmNlFNRWVKRzlxd2Z6SUNSME5PMWNXLTMwUHNwRFlsb3p1Q0hydHNBbHRIWHpYdUszZlFFZEFYRHV1UTlWQUkyZnlQeG51bWk?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOaDY1Y3F1Tnl0V2FiWGswQUIxLVNLdzlyNHNtMnNqLTF6cUxiSUxCYlZHTEIyaWhrN002TVFNN2dERk1Wc3BPa2FUNEItLWljVU1UM0ZvWlctVFlHaTJkNHIyMWRWd2paX1RIa0tmNlFNRWVKRzlxd2Z6SUNSME5PMWNXLTMwUHNwRFlsb3p1Q0hydHNBbHRIWHpYdUszZlFFZEFYRHV1UTlWQUkyZnlQeG51bWk?oc=5", "title": "IM Cannabis Q2 Results: EPS Loss Widens to $(0.34), Sales Down 40%", "content_text": "IM Cannabis Q2 Results: EPS Loss Widens to $(0.34), Sales Down 40%", "date_published": "2026-08-13T22:04:46+00:00", "authors": [{"name": "scanx.trade"}], "tags": ["Earnings", "IMCC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMCC", "name": "Im Cannabis Corp", "sentiment_url": "https://sharemaestro.com/sentiment/833d58bb-24b2-49c2-bc1b-67a13a4e0456/"}]}}, {"id": "source:4cb3f9dfa91d63a7007bf574673e64d868edc2f2d857bbddf9614e67f785c51c", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTFR3Wi1IaF9Ddk9JRUVMWlhJSnJyTGdTdHBuX1h1alV5d1ZWT2lhQVFaeUdFeTlGZ1R0SHBNMUFKdDI1a1MzNHBHS3pJcUg3T2tiU2lKZ2tSNVJUSlFpcWE5dDFMYVpJeUxRSWU5aVdwdGFNTUoyLVhiR1NxSHBOZGI3dVR6Q09aQ0RlQm1Cb2RvazR3c254dlVLOEliak1IV3Fzdk1KOHFnYUNIRkpBblVXX3Z3a0ZPek9QcWRUdUlHOEVQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTFR3Wi1IaF9Ddk9JRUVMWlhJSnJyTGdTdHBuX1h1alV5d1ZWT2lhQVFaeUdFeTlGZ1R0SHBNMUFKdDI1a1MzNHBHS3pJcUg3T2tiU2lKZ2tSNVJUSlFpcWE5dDFMYVpJeUxRSWU5aVdwdGFNTUoyLVhiR1NxSHBOZGI3dVR6Q09aQ0RlQm1Cb2RvazR3c254dlVLOEliak1IV3Fzdk1KOHFnYUNIRkpBblVXX3Z3a0ZPek9QcWRUdUlHOEVQ?oc=5", "title": "IM Cannabis Posts Deeper Losses and Negative Equity in Second Quarter 2026", "content_text": "IM Cannabis Posts Deeper Losses and Negative Equity in Second Quarter 2026", "date_published": "2026-08-13T21:44:10+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "IMCC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMCC", "name": "Im Cannabis Corp", "sentiment_url": "https://sharemaestro.com/sentiment/833d58bb-24b2-49c2-bc1b-67a13a4e0456/"}]}}, {"id": "source:b7dd4804a9613a03f66b7bdff56e8e83ebc72e7147ac24ac45cc32db07644549", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPbVlPMG5DY1MtZEVTOTRXcnA4clpUdmxJWWkxRXhLZHU1OHZ4SFlHaUFKYmp3WTc5Vy01c09RNmk5Z29DT0IybXdLU0pFbC1QRW9USExDaTNOYUxIN1FTUjYxY3NHOUpCSmZ1SEZBTmdLdHdxdEtwdTZsX3dKbU9UM3l1ZUQ0WFgwTXRQTTZFTUtNVG1CcXpPa3JQSHFKZkRQYkhiU3ZsZFVnNnA5ay1wdjZGWm8?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPbVlPMG5DY1MtZEVTOTRXcnA4clpUdmxJWWkxRXhLZHU1OHZ4SFlHaUFKYmp3WTc5Vy01c09RNmk5Z29DT0IybXdLU0pFbC1QRW9USExDaTNOYUxIN1FTUjYxY3NHOUpCSmZ1SEZBTmdLdHdxdEtwdTZsX3dKbU9UM3l1ZUQ0WFgwTXRQTTZFTUtNVG1CcXpPa3JQSHFKZkRQYkhiU3ZsZFVnNnA5ay1wdjZGWm8?oc=5", "title": "Eton Pharmaceuticals earnings beat by $0.28, revenue topped estimates", "content_text": "Eton Pharmaceuticals (ETON) reported Q2 earnings of $0.35 per share, significantly beating the Zacks Consensus Estimate of $0.11, and revenues of $37.59 million, surpassing estimates by 38.12%. Despite strong financial performance and a 145.9% stock increase year-to-date, the company currently holds a Zacks Rank #5 (Strong Sell) due to unfavorable earnings estimate revision trends. Investors are advised to monitor future estimate revisions and management commentary.", "date_published": "2026-08-13T21:41:49+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:9f44275a82e843edb62a987c82bf73125fd444da6ba79e775587ae1bbe25f8f7", "url": "https://www.quiverquant.com/news/IM+Cannabis+Corp.+%28IMCC%29+Stock+Falls+on+Q2+2026+Earnings", "external_url": "https://www.quiverquant.com/news/IM+Cannabis+Corp.+%28IMCC%29+Stock+Falls+on+Q2+2026+Earnings", "title": "IM Cannabis Corp. (IMCC) Stock Falls on Q2 2026 Earnings", "content_text": "IM Cannabis Corp. (IMCC) reported a significant decline in Q2 2026 revenue, down 42.8% year-over-year to $5.4 million, with a net loss of $3.1 million. This financial performance led to a 1.9% drop in the stock price after market close. Institutional investors showed mixed activity, with some major firms decreasing their holdings while others, like STONEX GROUP INC. and BANK OF MONTREAL /CAN/, increased theirs.", "date_published": "2026-08-13T21:18:00+00:00", "authors": [{"name": "Quiver Quantitative"}], "tags": ["Earnings", "IMCC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMCC", "name": "Im Cannabis Corp", "sentiment_url": "https://sharemaestro.com/sentiment/833d58bb-24b2-49c2-bc1b-67a13a4e0456/"}]}}, {"id": "source:da2ac5f7d7e7a62f980a2a77120f080a8592a02900734cf5669e202a2453ffd8", "url": "https://finance.yahoo.com/healthcare/articles/hims-q2-deep-dive-ai-211700767.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-q2-deep-dive-ai-211700767.html", "title": "HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook", "content_text": "HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter's revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its non-GAAP loss of $0.09 per share was significantly below analysts' consensus estimates. Is now the time to buy HIMS? Find out in our full research report (it's free). Hims & Hers Health (HIMS) Q2 CY2026 Highlig", "date_published": "2026-08-13T21:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "Hims Hers Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/494d8676-2cc6-4860-bdb4-37e9e4702e1f/"}]}}, {"id": "source:c262f6a8cbd253386c4c6302124faa475da34b2a18cef249e946954da9f86cde", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOQWJzcDN1a05EaThRMnhFMWZtYnctaXB6WjJMRHMyTnI3WG5ZNzQ5MlJMdzhOa1BGelZQTDUtM2k2WkZyVzJaS0lDOEZZSjlwS0ptOHhYY1NkaTc4RjdzMnU4MnhYZFgxLXFXc0dIQkF1UzVWOFgxR2Z5dDZFcVFMYnVWR2RxUmczZG9zaGxvWWFRbHNWWE5iSWVXT2tvT1RNZlNZVjBvUzZob1E2ZE9BcV9qemtZN3czMEVCVi1RTUpzRVpWNUhDdWhXOWlpSXo5MmN6ckczQ2tadE1mMElRT1FJR3dKUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOQWJzcDN1a05EaThRMnhFMWZtYnctaXB6WjJMRHMyTnI3WG5ZNzQ5MlJMdzhOa1BGelZQTDUtM2k2WkZyVzJaS0lDOEZZSjlwS0ptOHhYY1NkaTc4RjdzMnU4MnhYZFgxLXFXc0dIQkF1UzVWOFgxR2Z5dDZFcVFMYnVWR2RxUmczZG9zaGxvWWFRbHNWWE5iSWVXT2tvT1RNZlNZVjBvUzZob1E2ZE9BcV9qemtZN3czMEVCVi1RTUpzRVpWNUhDdWhXOWlpSXo5MmN6ckczQ2tadE1mMElRT1FJR3dKUQ?oc=5", "title": "Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.28 EPS", "content_text": "Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.28 EPS", "date_published": "2026-08-13T21:16:10+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:26762b42d86c059f40104db1df5b11f3aca949c411ccfec23914353fbce0257a", "url": "https://www.stocktitan.net/sec-filings/LNTH/schedule-13g-a-lantheus-holdings-inc-amended-passive-investment-discl-58ee3a30f886.html", "external_url": "https://www.stocktitan.net/sec-filings/LNTH/schedule-13g-a-lantheus-holdings-inc-amended-passive-investment-discl-58ee3a30f886.html", "title": "Farallon group (LNTH) discloses 5.58M-share, 8.6% position in Lantheus", "content_text": "Farallon Capital Management, L.L.C. and its related funds have reported a beneficial ownership of 5,583,479 shares of Lantheus Holdings, Inc. common stock, which represents 8.6% of the outstanding class as of June 30, 2026. This disclosure was made via an amended Schedule 13G filing. The shares are held through various investment partnerships managed by Farallon Capital Management, L.L.C., with managing and senior managing members exercising shared voting and dispositive power.", "date_published": "2026-08-13T21:12:32+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "LNTH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LNTH", "name": "Lantheus Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/41a59536-c8b5-4d85-a0e6-acfdd4b6ccea/"}]}}, {"id": "source:c533d021e6bb176a6798a5370e330ec08464d8e7eed3a243c4329fce101b4f1b", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRm84cmxtTjJaMjV5c05TX1ZYbm9zWENrSUVSTjU4Uk5uTWlDcUNHRGVjRFZWcDdVOVk1YnBvV2hlMVVUWDFGTEpPN05nalh1Slg3bG55Yk1saDhGZ0o4dkpWNXNjZW8zQVF5UnNYWFlmTm1teGI4QU9IcEc4aFVVQUdJeV9OZ2NGLUFta3F1SVBTdUNVNDJyRTR1UWpBNXhCb3dMQU9zSzR4Ri11RjBDajdIYm1DazQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRm84cmxtTjJaMjV5c05TX1ZYbm9zWENrSUVSTjU4Uk5uTWlDcUNHRGVjRFZWcDdVOVk1YnBvV2hlMVVUWDFGTEpPN05nalh1Slg3bG55Yk1saDhGZ0o4dkpWNXNjZW8zQVF5UnNYWFlmTm1teGI4QU9IcEc4aFVVQUdJeV9OZ2NGLUFta3F1SVBTdUNVNDJyRTR1UWpBNXhCb3dMQU9zSzR4Ri11RjBDajdIYm1DazQ?oc=5", "title": "IM Cannabis Revenue Falls to C$16.3M as Half-Year Loss Widens", "content_text": "IM Cannabis Revenue Falls to C$16.3M as Half-Year Loss Widens", "date_published": "2026-08-13T21:02:00+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "IMCC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMCC", "name": "Im Cannabis Corp", "sentiment_url": "https://sharemaestro.com/sentiment/833d58bb-24b2-49c2-bc1b-67a13a4e0456/"}]}}, {"id": "source:8ce4c98957d64e8a56ca2ef6c5f5c661d5a1ed08714dd36a2856de584b5efec6", "url": "https://m.investing.com/news/earnings/eton-pharmaceuticals-soars-25-on-earnings-beat-raised-guidance-93CH-4859216?ampMode=1", "external_url": "https://m.investing.com/news/earnings/eton-pharmaceuticals-soars-25-on-earnings-beat-raised-guidance-93CH-4859216?ampMode=1", "title": "Eton Pharmaceuticals soars 25% on earnings beat, raised guidance", "content_text": "Eton Pharmaceuticals (NASDAQ:ETON) shares surged 25% after reporting strong second-quarter results that significantly exceeded analyst expectations. The company posted adjusted EPS of $0.43 and revenue of $37.6 million, driven by HEMANGEOL sales and growth in its rare disease portfolio. Eton also raised its full-year 2026 revenue guidance to over $145 million and increased its adjusted EBITDA margin target to at least 35%.", "date_published": "2026-08-13T20:41:58+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:b38e782f0a87402d0b18c9747359a2c55eab085eac39334e1cfaf0bf577e3001", "url": "https://www.stocktitan.net/sec-filings/IMCC/6-k-im-cannabis-corp-current-report-foreign-issuer-200ab7a286be.html", "external_url": "https://www.stocktitan.net/sec-filings/IMCC/6-k-im-cannabis-corp-current-report-foreign-issuer-200ab7a286be.html", "title": "IM Cannabis (Nasdaq: IMCC) revenue drops as losses mount and going concern risk cited", "content_text": "IM Cannabis Corp. (IMCC) reported a significant revenue drop and mounting losses for the first half of 2026, leading management to flag substantial doubt about the company's ability to continue as a going concern. Revenue fell to $16.268 million from $25.196 million year-over-year, with a net loss of $6.852 million. The company is pursuing cost-saving measures, additional financing, and the sale of its European-focused assets to address its financial challenges and non-compliance with Nasdaq's minimum bid price requirement.", "date_published": "2026-08-13T20:41:13+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Balance sheet", "IMCC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMCC", "name": "Im Cannabis Corp", "sentiment_url": "https://sharemaestro.com/sentiment/833d58bb-24b2-49c2-bc1b-67a13a4e0456/"}]}}, {"id": "source:c9b2eac1b7685b1573b2ff2265e37881d357fa8bfe66abb16e8128343bb87e79", "url": "https://www.prnewswire.com/news-releases/im-cannabis-corp-announces-second-quarter-and-first-half-2026-financial-results-302851407.html", "external_url": "https://www.prnewswire.com/news-releases/im-cannabis-corp-announces-second-quarter-and-first-half-2026-financial-results-302851407.html", "title": "IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results", "content_text": "IM Cannabis Corp. (IMC) announced its financial results for the second quarter and first half of 2026, reporting a decrease in revenue and an increased net loss compared to the same periods in 2025. For the first half of 2026, revenue was $16.3 million with a net loss of $6.9 million, and for the second quarter, revenue was $7.6 million with a net loss of $4.4 million. The company's balance sheet as of June 30, 2026, showed cash of $1.6 million and a total liabilities exceeding total assets, resulting in a shareholders' deficit of $5.5 million.", "date_published": "2026-08-13T20:41:13+00:00", "authors": [{"name": "PR Newswire"}], "tags": ["Earnings", "IMCC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMCC", "name": "Im Cannabis Corp", "sentiment_url": "https://sharemaestro.com/sentiment/833d58bb-24b2-49c2-bc1b-67a13a4e0456/"}]}}, {"id": "source:75d3b629b9080b5f0485359fbeddeb3b04d3727d50b996d45cf0822df454727b", "url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-84cbf7b0313f.html", "external_url": "https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-84cbf7b0313f.html", "title": "Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades", "content_text": "Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, sold a total of 216,613 shares of Class A Common Stock in two separate transactions on August 11 and August 12, 2026. The sales were open-market transactions, not pursuant to a Rule 10b5-1 trading plan, and involved weighted average prices of $17.70 and $17.40 per share respectively. Following these transactions, Daly's direct holdings in Class A Common Stock are 35,171 shares.", "date_published": "2026-08-13T20:40:40+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "AMRX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMRX", "name": "Amneal Pharmaceuticals, Inc. Class A Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/eb64bade-4c9e-49a5-a30d-539ebca2200e/"}]}}, {"id": "source:2fe4f000250b885c09f774fa02ef68a0e827bc39f862eb860c8266d0f1e2e4dd", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQ01OdC0zMmdDamUxM2dtY0ZOMy1kQVZRSl82SXAyWURfSjhaNG1MQzVYa2VMRDl1Ty1JaThzSUstUm40bnhnY1FoTUxKLUdKaFV1VERIQ01MNHNNVllhRzQ4RmlwSFlzdlREOG5nN0VTN3gxVndNcnlKYkw4VHJsWjVQZzhQRWZwbnRSWld5X0NvdlRtY0w5Wm1hOGU4UkNjYWhPc1k1R2lRM24ySW5jaHExb2U3cTNn?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQ01OdC0zMmdDamUxM2dtY0ZOMy1kQVZRSl82SXAyWURfSjhaNG1MQzVYa2VMRDl1Ty1JaThzSUstUm40bnhnY1FoTUxKLUdKaFV1VERIQ01MNHNNVllhRzQ4RmlwSFlzdlREOG5nN0VTN3gxVndNcnlKYkw4VHJsWjVQZzhQRWZwbnRSWld5X0NvdlRtY0w5Wm1hOGU4UkNjYWhPc1k1R2lRM24ySW5jaHExb2U3cTNn?oc=5", "title": "Eton Pharmaceuticals (NASDAQ: ETON) swings to H1 2026 profit on revenue jump", "content_text": "Eton Pharmaceuticals (NASDAQ: ETON) reported a significant financial turnaround, swinging to a profit in the first half of 2026 with net income of $13.1 million, compared to a net loss of $4.1 million in the same period of 2025. This improvement was driven by a substantial increase in revenues, reaching $61.8 million, primarily due to higher sales of INCRELEX\u00ae, GALZIN\u00ae, Carglumic Acid, and the addition of HEMANGEOL\u00ae. The company also strengthened its adjusted EBITDA and operating cash generation, while expanding its rare disease portfolio through strategic licensing deals.", "date_published": "2026-08-13T20:18:34+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZTS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZTS", "name": "Zoetis Inc", "sentiment_url": "https://sharemaestro.com/sentiment/41d60a13-a660-4aac-b968-f260cc88399b/"}]}}, {"id": "source:b5388ffe7977fcebc727431fa319db170f41a47c2fe6a1ec548b034a8b7c0f2b", "url": "https://www.globenewswire.com/news-release/2026/08/13/3344924/0/en/eton-pharmaceuticals-reports-second-quarter-2026-financial-results.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/13/3344924/0/en/eton-pharmaceuticals-reports-second-quarter-2026-financial-results.html", "title": "Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results", "content_text": "Eton Pharmaceuticals reported record Q2 2026 product sales of $37.6 million, a 99% increase year-over-year, and raised its full-year revenue guidance to over $145 million. The company's strong performance was driven by the successful relaunch of HEMANGEOL and growth across its rare disease portfolio, including the recent acquisition of ASN-001 and IMPAVIDO commercialization rights. Eton also achieved a Q2 2026 non-GAAP fully diluted EPS of $0.43 and an Adjusted EBITDA of $16.2 million.", "date_published": "2026-08-13T19:41:58+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:a45c7e04e2778d92dcc78decfc98b3e8d8cabc6ea4d973e4cf1aa5d16d547b51", "url": "https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-reports-second-quarter-2026-financial-jxsanggrcktm.html", "external_url": "https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-reports-second-quarter-2026-financial-jxsanggrcktm.html", "title": "Eton Now Expects 2026 Revenue to Exceed $145M After Q2", "content_text": "Eton Pharmaceuticals reported strong Q2 2026 financial results, with net revenue surging 99% year-over-year to $37.6 million. Driven by the successful relaunch of HEMANGEOL and growth across its rare disease portfolio, the company has raised its full-year 2026 revenue guidance to exceed $145 million and expects an Adjusted EBITDA margin of at least 35%. Eton also announced key pipeline advancements, including the licensing of ASN-001, an FDA Fast Track designation for AMGLIDIA, and the acquisition of U.S. commercialization rights for IMPAVIDO.", "date_published": "2026-08-13T19:41:58+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}, {"id": "source:f8e08e809cf14b1ea7ed303eb46a920cb9b3d15857bb9bf105f932e46728b0b4", "url": "https://finance.yahoo.com/healthcare/articles/centrum-reframes-healthy-aging-proactive-190000403.html", "external_url": "https://finance.yahoo.com/healthcare/articles/centrum-reframes-healthy-aging-proactive-190000403.html", "title": "Centrum Reframes Healthy Aging as a Proactive Practice for Adults 35 and Beyond", "content_text": "With the introduction of Centrum Age Defy alongside the trusted Centrum Silver portfolio, Centrum is helping redefine healthy aging as a lifelong journey, not a destination. Key Takeaways Centrum, the #1 doctor- and pharmacist-recommended multivitamin brand, is helping redefine healthy aging as a proactive, lifelong journey, encouraging adults to invest in their long-term health starting at age 35. Centrum's healthy aging portfolio now spans every stage of adulthood, with new Centrum Age Defy for adults ages 35+ alongside Centrum Silver for adults ages 50+. Actress, producer and entrepreneur K", "date_published": "2026-08-13T19:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "HLN"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "HLN", "name": "Haleon plc", "sentiment_url": "https://sharemaestro.com/sentiment/81891e30-1ea6-44ac-99f0-7ca30b109580/"}]}}, {"id": "source:089743f13550a0eb23280103b41e8105a37f127064163297e8ab53eb57fa0359", "url": "https://finance.yahoo.com/technology/ai/articles/michael-burry-sends-fresh-ai-184329662.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/michael-burry-sends-fresh-ai-184329662.html", "title": "Michael Burry Sends Fresh AI Warning on Nebius, Micron and Oracle", "content_text": "This article first appeared on GuruFocus. Michael Burry (Trades, Portfolio) has increased bearish positions tied to artificial intelligence and semiconductor stocks, while adding to selected long holdings, according to a Wednesday Substack post. Warning! GuruFocus has detected 3 Warning Signs with MU. Is MU fairly valued? Test your thesis with our free DCF calculator. Burry added to his short positions in Nebius Group (NASDAQ:NBIS), Micron Technology (NASDAQ:MU), Oracle (NYSE:ORCL) and the iShares Semiconductor ETF (NASDAQ:SOXX). The investor said he added to his NBIS position at $247, MU at $", "date_published": "2026-08-13T18:43:29+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZTS"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZTS", "name": "Zoetis Inc", "sentiment_url": "https://sharemaestro.com/sentiment/41d60a13-a660-4aac-b968-f260cc88399b/"}]}}, {"id": "source:907bebad6bdb21460dc5b7a44e3d614dff96801d92c1821dad763621af4b16ea", "url": "https://ca.finance.yahoo.com/quote/INDV/options?date=1829001600&straddle=false&type=all", "external_url": "https://ca.finance.yahoo.com/quote/INDV/options?date=1829001600&straddle=false&type=all", "title": "Indivior Pharmaceuticals, Inc. (INDV) Options Chain", "content_text": "This article provides the options chain for Indivior Pharmaceuticals, Inc. (INDV), listing both call and put options with their respective strike prices, last trade dates, prices, and other relevant data. It includes current stock performance and related pharmaceutical tickers.", "date_published": "2026-08-13T18:40:47+00:00", "authors": [{"name": "Yahoo! Finance Canada"}], "tags": ["Market update", "INDV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "INDV", "name": "Indivior PLC Ordinary Shares", "sentiment_url": "https://sharemaestro.com/sentiment/70a37aec-1dfd-4b2e-8c8c-99467b4d32e7/"}]}}, {"id": "source:ad0afb38c4ab5c516b97f9f9129b3f0dd6ee6e118a7fe94b85be954cb49f1d90", "url": "https://finance.yahoo.com/markets/stocks/articles/prestige-consumer-healthcare-pbh-bets-182234805.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/prestige-consumer-healthcare-pbh-bets-182234805.html", "title": "Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?", "content_text": "Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W. The first quarter fiscal 2027 earnings call, held August 6, showed a company beating its own targets even before Breathe Right and LaCorium Health joined the mix. But Clear Eyes, one of its historically strongest brands, is still working through a manufacturing bottleneck.Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover? Bull Case: A Diversified Machine Adding Fuel Fir", "date_published": "2026-08-13T18:22:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "PBH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PBH", "name": "Prestige Brand Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/d32aba5f-28f0-4259-a8c0-966ec848033c/"}]}}, {"id": "source:f687ca88d44b8346269757b2f5464410caf7e9eea843f7769ef30c66c174f505", "url": "https://www.nasdaq.com/articles/viatris-vtrs-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/viatris-vtrs-q2-2026-earnings-call-transcript", "title": "Viatris (VTRS) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- $3.8 billion, representing 3.5% operational growth year over year driven by strength in Greater China and complex generics in North America.Adjusted EBITDA -- $1.2 billion, reflecting an 8% operational increase versus the prior year due to operating leverage and cost discipline.Adjusted EPS -- $0.69, a 9% operational in", "date_published": "2026-08-13T18:13:22+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "VTRS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VTRS", "name": "Viatris Inc", "sentiment_url": "https://sharemaestro.com/sentiment/fea876ac-6f7d-46b8-a241-170093a0833c/"}]}}, {"id": "source:26621352c61d0b750159a97231f49826e1b0292e44f87574a0e92362a2850c66", "url": "https://finance.yahoo.com/healthcare/articles/asceniv-help-adma-stock-combat-174700632.html", "external_url": "https://finance.yahoo.com/healthcare/articles/asceniv-help-adma-stock-combat-174700632.html", "title": "Can Asceniv Help ADMA Stock Combat IG Market Challenges?", "content_text": "ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases. The company currently markets three FDA-approved plasma-derived biologics: Asceniv (immune globulin intravenous \u2013 slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); Bivigam (immune globulin intravenous) for the treatment of PI; and NABI-HB (hepatitis B immune globulin) to provide enhanced immunity against the hepatitis B virus. Asceniv w", "date_published": "2026-08-13T17:47:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TAK"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TAK", "name": "Takeda Pharmaceutical Co Ltd ADR", "sentiment_url": "https://sharemaestro.com/sentiment/31f31298-a544-49e1-8ab7-d3caae9549ed/"}]}}, {"id": "source:f0a7380096de4910a9affacdf3f89f3158618d1b0511c0aeef0500b94f109bec", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRzNVMGJoV1V2OFJvSU9vakdlcFVlOU5EYWpxcFJuZ0VYUHlNZmFWNWZZTlkyQ21Oc0lQQTkxT1ZPS0tKb1FYVzhCTWNXbVhacUpIbTdmSnpJV1RFUkVfWE8yODViTF90ZGNwWGZzeHZiYURhV0syaGNxTVZKUTBoMXpWQ2IzRWpvYWljT1JzT2d4MEZ1ZDhWeGstOEJncTE0QVhGUDdXZG9fNFVNM216U3BEUUM4RVItU2VV?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRzNVMGJoV1V2OFJvSU9vakdlcFVlOU5EYWpxcFJuZ0VYUHlNZmFWNWZZTlkyQ21Oc0lQQTkxT1ZPS0tKb1FYVzhCTWNXbVhacUpIbTdmSnpJV1RFUkVfWE8yODViTF90ZGNwWGZzeHZiYURhV0syaGNxTVZKUTBoMXpWQ2IzRWpvYWljT1JzT2d4MEZ1ZDhWeGstOEJncTE0QVhGUDdXZG9fNFVNM216U3BEUUM4RVItU2VV?oc=5", "title": "LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth", "content_text": "Liquidia Corporation LQDA reported second-quarter 2026 earnings per share (EPS) of 74 cents, which topped the Zacks Consensus Estimate of 70 cents. In the year-ago quarter, the company reported a loss per share of 49 cents. Total revenues surged to $171.7 million from $8.8 million in the year-ago quarter and beat the Zacks Consensus Estimate of $165 million. The quarterly performance was powered by continued adoption of lead drug Yutrepia. However, shares were down 10% following the second-quarter results. Shares of LQDA have surged 128.5% year to date compared with the industry's growth of 5.", "date_published": "2026-08-13T17:47:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "UTHR"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "UTHR", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/fbffdb96-6605-4c75-a92b-ecbfdce86d82/"}]}}, {"id": "source:d0f2b24ba63028b6a073e17af001171653f4f94f939c6bcd639c66734f23fe1e", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRTJYNS1jUGNBVEtUSjZvUnNZbG5vMnRicm1XLXdod2plUThlNHFBVEdRUGQxS3JlNXhSRWVXTU5hVWdUZ18yMzBKOXlLU0NuaXM3dVRVc3pwcFg2TXR2Ym9zZEppMmM1TnlEMjYxbnVjam1Iby1jaFZWdWxGRWpMN0lZTFJ2b1MxQ2MtdGlmcUVnVC1mVkJQd0s0WENIVFMzWEhFX1ktdmdTTGRKRXMwd0VRckNyWmx1d3YzZEZNYk4?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRTJYNS1jUGNBVEtUSjZvUnNZbG5vMnRicm1XLXdod2plUThlNHFBVEdRUGQxS3JlNXhSRWVXTU5hVWdUZ18yMzBKOXlLU0NuaXM3dVRVc3pwcFg2TXR2Ym9zZEppMmM1TnlEMjYxbnVjam1Iby1jaFZWdWxGRWpMN0lZTFJ2b1MxQ2MtdGlmcUVnVC1mVkJQd0s0WENIVFMzWEhFX1ktdmdTTGRKRXMwd0VRckNyWmx1d3YzZEZNYk4?oc=5", "title": "Amylyx (AMLX) Q2 2026 Earnings Call Transcript", "content_text": "Amylyx (AMLX) Q2 2026 Earnings Call Transcript", "date_published": "2026-08-13T17:07:09+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Earnings", "AMLX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMLX", "name": "Amylyx Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/9542732c-dd8b-415f-9b0f-63df1f29d967/"}]}}, {"id": "source:8b9e0c6df2e678d44e662172b5a6883c5adb168a8ea93d4b7ee0ec30d2e6c40a", "url": "https://stocktwits.com/news-articles/markets/equity/liquidia-ceo-roger-jeffs-says-demand-for-inhaled-lung-disease-drug-is-growing-amid-q2-revenue-beat/cZo85K6RJgD", "external_url": "https://stocktwits.com/news-articles/markets/equity/liquidia-ceo-roger-jeffs-says-demand-for-inhaled-lung-disease-drug-is-growing-amid-q2-revenue-beat/cZo85K6RJgD", "title": "Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat", "content_text": "Liquidia reported a strong second quarter, with total revenue of $171.7 million, exceeding Wall Street estimates, largely driven by sales of its inhaled lung disease drug, Yutrepia. Since its launch in June 2025, Yutrepia has received approximately 5,900 unique patient prescriptions and contributed significantly to the company's net product sales, which surged to $170.4 million. CEO Roger Jeffs noted the sustained adoption of Yutrepia, highlighting its increasing share in the growing inhaled prostacyclin market.", "date_published": "2026-08-13T15:10:35+00:00", "authors": [{"name": "Stocktwits"}], "tags": ["Earnings", "LQDA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LQDA", "name": "Liquidia Technologies Inc", "sentiment_url": "https://sharemaestro.com/sentiment/8e5d7b6f-961c-47d1-88c6-1f484b726a2f/"}]}}, {"id": "source:ed9a36855118876ed627f0c298d3abb9c3b9a82bc88e71a10131e735706741fc", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQWkpncm1NOVAxRml4V25EdUxTcVBKY0FhTmpLM1c3cUkyYnpVY1J6WGx1bk4tbWNpZVNvUHB4Uml5OVRDUHR3ZkNVZ1VfZF9jN0owNWhWT0M2UVZMS0t6Vk1fZkRKZTl4Y1lBSWxHWEtzYUJmMURnRm56NFhLUnNfRVUtX0ZTVWc5cnladkU5b1JWZXhlM3dTZV9oMVBiVXEtYnJBbFJUTDlhdW0xR2NhU1BOYnVFX0xVMmtFbUxSUzBVX0d4c0xjUnN0cWZzY3pKREJuZTd4M09ZQ0NMcm9oTU9EWDZyQ3NNVFHSAe8BQVVfeXFMTXJfV1E0T1o1M1ZRalIzVVFYTzEySkJlVmRlZUlsdjktMU1CUldKenlQRDBmYlNfS05BYTZNNWFGSzZKOVJfTHU3T2RoMHVQWC1JaUNLbjB5b1UxRm1TVDdWdzVCZmNFcF9BOGtPNEN1T2xOeTN1NlYza1E3SEhhZDRkRDZ2cUZjamhMRjJCS3VxOXNrdU90Z0FhbUU3OVZSNEdMWTRYenZUSEdmekd0WmdUUzkxZnQxVTlIdF9DWnhrZnVYb2pUUDBUVG82RFVqZ29fU2traFdFWDlRZkY2Y1lHNnJhbGVhelBBYVFIbGc?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Phibro Animal Health (PAHC) Stock Looks Undervalued On Earnings Yet Mixed Elsewhere", "content_text": "Phibro Animal Health (PAHC) Stock Looks Undervalued On Earnings Yet Mixed Elsewhere", "date_published": "2026-08-13T14:30:50+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Earnings", "PAHC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PAHC", "name": "Phibro Animal Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/064612ef-ec89-469d-8e5b-b34c033cf092/"}]}}, {"id": "source:52e4cc1326d710dbea14acd5e94cb950628cf163f6093b6f72528796e5245c02", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings", "content_text": "United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings", "date_published": "2026-08-13T14:30:50+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "UTHR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UTHR", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/fbffdb96-6605-4c75-a92b-ecbfdce86d82/"}]}}, {"id": "source:e0ce39f8d11f8a075f09ec34e25ee880d2a22b34aa9e5bcf3a22a014e4bba843", "url": "https://www.stocktitan.net/sec-filings/RDY/6-k-dr-reddys-laboratories-ltd-current-report-foreign-issuer-81e4a41f3410.html", "external_url": "https://www.stocktitan.net/sec-filings/RDY/6-k-dr-reddys-laboratories-ltd-current-report-foreign-issuer-81e4a41f3410.html", "title": "Dr. Reddy\u2019s Laboratories (RDY) CEO API & Services Deepak Sapra resigns effective November 12, 2026", "content_text": "Dr. Reddy\u2019s Laboratories announced that Deepak Sapra, CEO of API & Services and a Senior Management Personnel, has resigned to pursue outside opportunities. His resignation is effective November 12, 2026, and he will remain with the company until then to ensure a smooth transition of his responsibilities. Sapra has been with Dr. Reddy's for over 23 years, since 2003.", "date_published": "2026-08-13T14:11:24+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "RDY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RDY", "name": "Dr. Reddy\u2019s Laboratories Ltd ADR", "sentiment_url": "https://sharemaestro.com/sentiment/a622687e-ec18-4cc0-88dd-9821b08b2e8d/"}]}}, {"id": "source:e79d8d6e14f60efb271f743a5569add8a54edb8a03ed780dca3d5422dbcbe9b5", "url": "https://pulse2.com/liquidia-yutrepia-reaches-5000-patients-as-inhaled-prostacyclin-market-expands-nearly-40", "external_url": "https://pulse2.com/liquidia-yutrepia-reaches-5000-patients-as-inhaled-prostacyclin-market-expands-nearly-40", "title": "Liquidia: YUTREPIA Reaches 5,000+ Patients As Inhaled Prostacyclin Market Expands Nearly 40%", "content_text": "Liquidia's YUTREPIA has reached over 5,000 patients and generated $170.4 million in Q2 net product sales, contributing to a nearly 40% expansion of the inhaled prostacyclin market since its launch. The company has seen four consecutive quarters of increasing profitability and is pursuing a broader strategy with its L606 extended-release formulation to expand its inhaled treprostinil franchise.", "date_published": "2026-08-13T14:10:35+00:00", "authors": [{"name": "Pulse 2.0"}], "tags": ["Earnings", "LQDA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LQDA", "name": "Liquidia Technologies Inc", "sentiment_url": "https://sharemaestro.com/sentiment/8e5d7b6f-961c-47d1-88c6-1f484b726a2f/"}]}}]}